Physician profile
Julia Malin
NPI 1881759355
$10,779.16
in general payments reported to CMS, 2019-2025
43 companies · $1,426 in 2025
The $1,426 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,034 · 2020: $962 · 2021: $1,683 · 2022: $1,649 · 2023: $2,002 · 2024: $2,024 · 2025: $1,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,358 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,357.55 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,734.02 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,732.82 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Abbvie INC. | $1,585.32 | 2021-2025 | |
| Novo Nordisk INC | $839.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $833.12 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $618.34 | 2022-2025 | Rexulti, Nuedexta |
| Astellas Pharma US INC | $380.84 | 2020-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $319.05 | 2020-2025 | Kisunla, Emgality, Reyvow |
| Abbott Laboratories | $298.51 | 2024-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.05 | 2019-2024 | Jardiance |
| Avanir Pharmaceuticals, INC. | $247.87 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $225.28 | 2019-2022 | |
| Axsome Therapeutics, INC. | $192.94 | 2023-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $157.21 | 2023 | Quviviq |
| Allergan, INC. | $137.57 | 2019-2020 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Malin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.